Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by YESID ALVARADO and NAVEEN PEMMARAJU.
YESID ALVARADO
Connection Strength
2.437
NAVEEN PEMMARAJU
  1. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.
    View in: PubMed
    Score: 0.242
  2. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Apr 09.
    View in: PubMed
    Score: 0.062
  3. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 Apr 04.
    View in: PubMed
    Score: 0.062
  4. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024 Apr; 11(4):e287-e298.
    View in: PubMed
    Score: 0.062
  5. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J. 2023 09 21; 13(1):148.
    View in: PubMed
    Score: 0.060
  6. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023 10; 98(10):1619-1626.
    View in: PubMed
    Score: 0.059
  7. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56.
    View in: PubMed
    Score: 0.057
  8. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 Nov; 97(11):1427-1434.
    View in: PubMed
    Score: 0.056
  9. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022 Nov; 97(11):1413-1418.
    View in: PubMed
    Score: 0.056
  10. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid. 2022 Oct; 1(10):EVIDoa2200034.
    View in: PubMed
    Score: 0.056
  11. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043.
    View in: PubMed
    Score: 0.055
  12. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 09; 63(9):2161-2170.
    View in: PubMed
    Score: 0.054
  13. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022 07; 97(7):856-864.
    View in: PubMed
    Score: 0.054
  14. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2022 05; 97(5):574-582.
    View in: PubMed
    Score: 0.054
  15. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer. 2021 11 15; 127(22):4213-4220.
    View in: PubMed
    Score: 0.052
  16. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
    View in: PubMed
    Score: 0.052
  17. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561.
    View in: PubMed
    Score: 0.052
  18. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.
    View in: PubMed
    Score: 0.052
  19. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778.
    View in: PubMed
    Score: 0.051
  20. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021 04 27; 5(8):2173-2183.
    View in: PubMed
    Score: 0.051
  21. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021 07 15; 127(14):2489-2499.
    View in: PubMed
    Score: 0.051
  22. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J. 2021 03 17; 11(3):60.
    View in: PubMed
    Score: 0.050
  23. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898.
    View in: PubMed
    Score: 0.050
  24. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213.
    View in: PubMed
    Score: 0.050
  25. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291.
    View in: PubMed
    Score: 0.050
  26. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.
    View in: PubMed
    Score: 0.049
  27. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.
    View in: PubMed
    Score: 0.048
  28. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
    View in: PubMed
    Score: 0.048
  29. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leuk Res. 2020 07; 94:106369.
    View in: PubMed
    Score: 0.048
  30. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020 04 14; 4(7):1311-1320.
    View in: PubMed
    Score: 0.047
  31. Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Lymphoma. 2020 08; 61(8):1943-1953.
    View in: PubMed
    Score: 0.047
  32. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
    View in: PubMed
    Score: 0.047
  33. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020 02 11; 4(3):482-495.
    View in: PubMed
    Score: 0.047
  34. Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.
    View in: PubMed
    Score: 0.046
  35. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
    View in: PubMed
    Score: 0.045
  36. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma. 2019 09; 60(9):2207-2213.
    View in: PubMed
    Score: 0.044
  37. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 07; 60(7):1767-1774.
    View in: PubMed
    Score: 0.043
  38. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37.
    View in: PubMed
    Score: 0.043
  39. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.042
  40. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
    View in: PubMed
    Score: 0.042
  41. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747.
    View in: PubMed
    Score: 0.041
  42. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. 2018 Apr; 5(4):e136-e146.
    View in: PubMed
    Score: 0.041
  43. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
    View in: PubMed
    Score: 0.041
  44. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99.
    View in: PubMed
    Score: 0.040
  45. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.